ClinicalTrials.gg
RecruitingNCT07717710Updated Oct 9, 2026

Ivabradine for Heart Rate Reduction During Exercise in Healthy Adults

An Early Phase 1 interventional study of Ivabradine (single oral dose) in Healthy Adult, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of British Columbia · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Motor Activity by University of British Columbia — 24 open to participants now, 26 under way, none of them phase 3. Motor Activity · University of British Columbia.

Planned enrollment
71st of 92
20 · median 61
Started
2026
with 6 others
Phase 1
3 of 96
1 open now
Primary completion
2026-12
later than 9 of 25 live
Registered
95th of 96
by date

Among the 96 studies in Motor Activity by University of British Columbia, this one is the 71st largest by planned enrollment of the 92 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 9 of the 25 other live ones, and was the 95th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

24 of the 96 studies in Motor Activity by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 24 open studies →

Where they have run

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Motor Activity by University of British Columbia, or all of them as a file.
02

Study summary

During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood.

Studying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps.

This study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age.

Participants will:

  • Attend three visits at SportsCardiologyBC in Vancouver
  • Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise
  • Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3)
  • Be monitored for side effects including slow heart rate, visual symptoms, and headache.
Read the detailed description

Heart rate and stroke volume are generally considered as two independent factors which influence cardiac output, yet they are interlinked by cellular (e.g., calcium handling) and hemodynamic (e.g., diastolic pressure decay) mechanisms. Delineating how heart rate and stroke volume influence cardiac output and exercise capacity, even within healthy individuals, has historically been experimentally difficult as pharmacologic perturbations, such as beta-adrenergic antagonists, influence both heart rate and heart muscle performance. Ivabradine selectively reduces heart rate in a dose-dependent manner, without impacting myocardial contractility, cardiac afterload, or venous return. However, it has largely been studied in clinical outcome trials in adults with heart failure, or safety studies in younger healthy adults. As such, there is a knowledge gap on how ivabradine influences heart rate and exercise capacity in healthy younger and older adults.

Study Purpose To characterize the effects of two single doses of ivabradine (7.5 mg and 12.5 mg) on heart rate during incremental exercise in younger and older healthy adults.

Exploratory Aim To assess the safety and tolerability of two single doses of ivabradine (7.5 mg and 12.5 mg) in younger and older healthy adults.

Hypothesis Ivabradine will produce dose-dependent reductions in peak exercise heart rate and heart rate/work-rate relationships (anticipated to be approximately 10-15%, on average).

Research Design Unblinded, non-randomized, repeated measures design.

Study Visits Visit 1 (1.5 hours): Screening, consent, assessments of anthropometrics, seated heart rate and blood pressure, a resting 12-lead electrocardiogram, and a cardiopulmonary exercise test with 12-lead electrocardiogram. Pre-menopausal females will also be required to complete a urine pregnancy test and confirm a negative result prior to participation.

Visits 2 and 3 (4 hours each): A single oral dose of ivabradine will be administered at each visit: 7.5 mg at Visit 2 and 12.5 mg at Visit 3. Doses are administered in this fixed order so that all participants are observed at the lower dose before proceeding to the higher dose.

Following drug administration, participants will be seated and observed for 90 minutes with continuous heart rate monitoring and blood pressure recorded at 15-minute intervals. Participants will then complete an incremental exercise test on a cycle ergometer with 12-lead ECG monitoring, following the same work-rate protocol used in Visit 1. Following exercise, participants will be seated and observed for 120 minutes with continuous heart rate monitoring and blood pressure recorded at 15-minute intervals.

Statistical Analysis Data will be analyzed using SPSS Statistics (v.30, IBM Inc). Normality will be assessed by the Shapiro-Wilk test. Omnibus testing will be conducted using analysis of variance (ANOVA), the Friedman test, or the Kruskal-Wallis test with significant effects tested post hoc. If all compared groups or conditions approximate a normal distribution, data will be presented as mean ± standard deviation with paired comparisons made using t-tests. Otherwise, data will be presented as median (inter-quartile range) with paired comparisons made using the Mann-Whitney U or Wilcoxon Signed Rank tests. Associations will be explored with Pearson correlations and linear regression.

Sample Size Justification Based on existing literature describing the effect of ivabradine on heart rate during exercise in healthy adults, a sample size of 20 provides 95% power to detect a 5 beats per minute difference between 7.5 mg and 12.5 mg trials, assuming a standard deviation of 5 beats per minute and a two-tailed alpha of 0.05 adjusted for three post-hoc paired t-tests.

03

Conditions studied

  • Healthy Adult

Browse trials for

Keywords

  • Heart rate regulation
  • Stroke volume
  • Cardiac output
  • Exercise
  • Exercise capacity
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females aged 19-39 years, and 60-79 years
  • Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week

Exclusion criteria

Exclusion Criteria:

  • History of any cardiovascular condition, including hypertension
  • Use of any chronic medication
  • History of any respiratory condition, including asthma
  • Smoking, including cannabis or vaping in the past year
  • History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness
  • Seated blood pressure ≥130/90 or \<100/60 mmHg
  • \<20 or >32 kg/m2
  • Non-sinus rhythm or abnormalities on 12-lead (ECG)
  • Pregnant, breastfeeding, or women of not using appropriate
  • Current or recent (past year) participation in >150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia)
  • Any condition that prevents vigorous exercise from being performed safely
  • Seated resting heart rate \<60 beats per minute
  • Prolonged (e.g., long QT syndrome)
  • Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block
  • Use of strong cytochrome P450 () inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels
  • Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine
  • Lactose intolerance, as ivabradine contains lactose
  • Known allergy/ to ivabradine or to any ingredient in the formulation or component of the container
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Ivabradine

    All participants receive two single oral doses of ivabradine in a fixed sequence across separate experimental visits.

    Drug: Ivabradine (single oral dose)

Interventions

  • DrugIvabradineStudies of IvabradineIvabradine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single oral dose of ivabradine is administered at each experimental visit, in a fixed order: 7.5 mg at Visit 2 (one 7.5 mg tablet), and 12.5 mg at Visit 3 (one 7.5 mg + one 5 mg tablet). Ivabradine is a selective hyperpolarization-activated cyclic nucleotide-gated transmembrane (HCN4) channel inhibitor that reduces heart rate without affecting myocardial contractility.

06

What researchers measure

Primary outcomes

  1. Heart rate, peak

    Highest heart rate achieved during the cardiopulmonary exercise test.

    Time frame: Within 30 minutes of exercise onset

Secondary outcomes

  1. Heart rate, resting

    Average heart rate over the 15 minutes of rest prior to the cardiopulmonary exercise test.

    Time frame: Within 15 minutes prior to exercise onset

  2. Heart rate/work rate

    Highest heart rate divided by the highest work rate achieved during the cardiopulmonary exercise test.

    Time frame: Within 30 minutes of exercise onset

  3. Incidence of visual symptoms

    Frequency of self-reported visual symptoms (phosphenes) assessed by standardized symptom questionnaire at 15-minute intervals during pre- and post-exercise observation periods.

    Time frame: Within 4 hours post-dose administration

  4. Incidence of headache

    Frequency of self-reported headache assessed by standardized symptom questionnaire at 15-minute intervals during pre- and post-exercise observation periods.

    Time frame: Within 4 hours post-dose administration

  5. Incidence of bradycardia

    Frequency of: (1) resting heart rate \<60 beats per minute; (2) resting heart rate \<50 beats per minute; and (3) a decrease in resting heart rate of \>10 beats per minute from pre-dose baseline, assessed by continuous heart rate monitoring during pre- and post-exercise observation periods.

    Time frame: Within 4 hours post-dose administration

07

Study locations

1 of 1 sites recruiting
  • SportsCardiologyBC, UBC Hospital
    Vancouver, British Columbia V6T 2B5, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 2 months after the start.

Of 73 non-industry phase 1 interventional studies under Motor Activity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 2 months is below that.

Counting every sponsor, half of 75 studies reached it within 20 months; a quarter within 11 and three quarters within 43.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 21, 2026
StartActual
Oct 1, 2026was Aug 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
SportsCardiologyBC, UBC Hospital is now Recruiting
Oct 9, 2026
Start date
Aug 1, 2026→Oct 1, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    SportsCardiologyBC, UBC Hospital is now Recruiting
    Start date Aug 1, 2026→Oct 1, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07717710
Responsible party
Nathaniel Moulson (Clinical Assistant Professor, Department of Medicine, University of British Columbia) — Principal investigator
First posted
Jul 21, 2026
Start date
Oct 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

Stephen P Wright, PhD
Contact
stephen.wright@ubc.ca
604-806-9292
Nathaniel Moulson, MD, MPH
Contact
nathaniel.moulson2@vch.ca
604-822-9494

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivabradine

Start the discussion